Table 2 Baseline demographics and characteristics by Month 1 migraine response and treatment
|  | ≥75% | 50–< 75% | 25–< 50% | < 25% | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
100 mg (n = 110) | 300 mg (n = 129) | Placebo (n = 57) | 100 mg (n = 84) | 300 mg (n = 83) | Placebo (n = 75) | 100 mg (n = 59) | 300 mg (n = 58) | Placebo (n = 81) | 100 mg (n = 103) | 300 mg (n = 80) | Placebo (n = 153) | |
Mean age, years (SD) | 42.1 (11.4) | 41.6 (10.1) | 40.5 (12.3) | 41.4 (11.2) | 40.8 (10.7) | 39.3 (10.9) | 37.9 (11.3) | 40.2 (10.0) | 39.6 (10.2) | 41.4 (12.5) | 40.9 (10.8) | 39.5 (11.7) |
Sex: female, n (%) | 92 (83.6) | 115 (89.1) | 49 (86.0) | 76 (90.5) | 75 (90.4) | 66 (88.0) | 50 (84.7) | 56 (96.6) | 72 (88.9) | 89 (86.4) | 68 (85.0) | 138 (90.2) |
Race, n (%) | ||||||||||||
 White | 104 (94.5) | 121 (93.8) | 51 (89.5) | 81 (96.4) | 78 (94.0) | 59 (78.7) | 56 (94.9) | 51 (87.9) | 74 (91.4) | 91 (88.3) | 72 (90.0) | 137 (89.5) |
 Black or African American | 6 (5.5) | 6 (4.7) | 4 (7.0) | 3 (3.6) | 3 (3.6) | 15 (20.0) | 3 (5.1) | 7 (12.1) | 6 (7.4) | 9 (8.7) | 7 (8.8) | 13 (8.5) |
 Other | 0 | 2 (1.6) | 2 (3.5) | 0 | 2 (2.4) | 1 (1.3) | 0 | 0 | 1 (1.2) | 3 (2.9) | 1 (1.3) | 3 (2.0) |
Mean BMI, kg/m2 (SD) | 26.1 (4.1) | 26.3 (4.6) | 27.2 (5.0) | 25.6 (5.2) | 26.3 (5.0) | 27.1 (5.4) | 27.2 (5.5) | 25.0 (4.3) | 27.0 (6.0) | 27.0 (5.3) | 27.1 (6.0) | 26.9 (5.7) |
Mean age at diagnosis, years (SD) | 23.2 (10.4) | 22.5 (9.3) | 22.2 (10.5) | 22.1 (10.2) | 22.0 (9.5) | 23.3 (9.1) | 24.1 (12.2) | 21.4 (9.1) | 22.8 (9.7) | 22.0 (10.3) | 21.8 (9.4) | 22.3 (10.4) |
Mean duration of migraine diagnosis, years (SD) | 18.9 (12.4) | 19.1 (11.5) | 18.3 (13.5) | 19.3 (11.4) | 18.8 (11.2) | 16.0 (10.4) | 13.8 (10.1) | 18.7 (12.1) | 16.8 (10.0) | 19.4 (13.3) | 19.1 (11.6) | 17.2 (12.3) |
Mean duration of chronic migraine, years (SD) | 10.4 (11.9) | 11.2 (11.2) | 12.3 (12.4) | 10.3 (10.8) | 13.5 (12.5) | 9.5 (9.8) | 10.7 (11.0) | 12.9 (10.6) | 10.4 (9.2) | 14.3 (12.4) | 12.6 (10.0) | 13.1 (11.5) |
Mean baseline MHDs (SD) | 19.6 (2.6) | 20.0 (3.3) | 21.1 (3.0) | 20.4 (3.1) | 20.4 (3.0) | 20.7 (2.8) | 20.4 (3.0) | 20.8 (3.3) | 20.5 (3.0) | 21.1 (3.5) | 21.0 (3.3) | 20.4 (3.1) |
Mean baseline MMDs (SD) | 15.4 (4.0) | 14.8 (4.6) | 16.2 (4.7) | 16.2 (4.7) | 16.2 (4.9) | 16.7 (4.0) | 16.5 (4.5) | 17.2 (4.3) | 16.6 (4.4) | 16.5 (5.2) | 17.2 (4.8) | 15.8 (4.8) |
MOH diagnosis, n (%) | 45 (40.9) | 54 (41.9) | 23 (40.4) | 33 (39.3) | 32 (38.6) | 28 (37.3) | 22 (37.3) | 28 (48.3) | 33 (40.7) | 39 (37.9) | 33 (41.3) | 61 (39.9) |
Mean HIT-6 total score (SD) | 64.1 (4.9) | 64.4 (5.1) | 63.8 (6.3) | 65.6 (4.9) | 65.1 (4.7) | 64.8 (5.4) | 66.1 (4.2) | 66.5 (5.3) | 65.3 (5.0) | 64.8 (5.4) | 65.1 (4.7) | 64.9 (5.4) |